Next Generation BioMimics 3D® Stent


Biomimics 3D Stent
Deborah’s Clinical Research Department is working on cutting–edge research for the next generation of stents.

Developed by Veryan and based on biomimicry, the new BioMimics 3D® stent technology involves adapting traditional straight stent designs to a patented three-dimensional helical shape, which more closely mimics the natural geometry of the human vascular system. BioMimics 3D technology is designed to enhance clinical performance by improving flow conditions and biomechanical performance of stented vessels. The advanced, biomimetic design of the BioMimics 3D stent is intended to provide more flexibility — as well as kink and fracture resistance, in comparison to other laser-cut nitinol tube stents — making its unique design of particular importance in the hostile environment of the femoropopliteal artery.

The BioMimics 3D stent has a unique helical curvature to impart natural geometry to the diseased artery, promoting secondary (swirling) flow and elevated hemodynamic shear stress, which has a protective effect on the endothelium. The helical geometry of the BioMimics 3D femoropopliteal stent is also designed to enable coil-spring shortening of the stented segment during knee flexion and thus mitigate the risk of stented segment compression causing localized strains, which in a straight stent may lead to stent fracture and chronic vascular injury.

“We are very excited to be working with this revolutionary new stent, which we expect will soon become state of the art,” says Vincent Varghese, DO, Attending, Interventional Cardiology and Endovascular Medicine, and lead researcher on the study. “The previously completed MIMICS-1 trial demonstrated significantly improved patency of the BioMimics stent in comparison to traditional straight stents, which translated into less repeat procedures for patients. The currently enrolling MIMICS-2 study will further evaluate the BioMimics stent in a larger population, with early indications suggesting that this may be a valuable tool in treating peripheral arterial disease.”